Seroatlas · Human Serome Atlas

SLC17A8

Vesicular glutamate transporter 3

Also known as: DFNA25, VGLU3_HUMAN, VGLUT3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8NDX2
Gene
SLC17A8
Ensembl
ENSG00000179520
Chromosome
12
Canonical length
589 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Subcellular location
Endoplasmic reticulum

OverviewNCBI Gene

This gene encodes a vesicular glutamate transporter. The encoded protein transports the neurotransmitter glutamate into synaptic vesicles before it is released into the synaptic cleft. Mutations in this gene are the cause of autosomal-dominant nonsyndromic type 25 deafness. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010]

Canonical amino-acid sequenceUniProt

589 residues, UniProt reviewed canonical sequence.

>Q8NDX2|SLC17A8
     1  MPFKAFDTFK EKILKPGKEG VKNAVGDSLG ILQRKIDGTT EEEDNIELNE EGRPVQTSRP
    61  SPPLCDCHCC GLPKRYIIAI MSGLGFCISF GIRCNLGVAI VEMVNNSTVY VDGKPEIQTA
   121  QFNWDPETVG LIHGSFFWGY IMTQIPGGFI SNKFAANRVF GAAIFLTSTL NMFIPSAARV
   181  HYGCVMCVRI LQGLVEGVTY PACHGMWSKW APPLERSRLA TTSFCGSYAG AVVAMPLAGV
   241  LVQYIGWSSV FYIYGMFGII WYMFWLLQAY ECPAAHPTIS NEEKTYIETS IGEGANVVSL
   301  SKFSTPWKRF FTSLPVYAII VANFCRSWTF YLLLISQPAY FEEVFGFAIS KVGLLSAVPH
   361  MVMTIVVPIG GQLADYLRSR QILTTTAVRK IMNCGGFGME ATLLLVVGFS HTKGVAISFL
   421  VLAVGFSGFA ISGFNVNHLD IAPRYASILM GISNGVGTLS GMVCPLIVGA MTRHKTREEW
   481  QNVFLIAALV HYSGVIFYGV FASGEKQEWA DPENLSEEKC GIIDQDELAE EIELNHESFA
   541  SPKKKMSYGA TSQNCEVQKK EWKGQRGATL DEEELTSYQN EERNFSTIS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC17A8 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
4.9 nTPM

Expression across tissuesHPA

Tissue

  • small intestine: 4.9 nTPM
  • thymus: 1.3 nTPM
  • retina: 1.1 nTPM
  • basal ganglia: 0.9 nTPM
  • hypothalamus: 0.9 nTPM
  • amygdala: 0.8 nTPM

Single-cell type

  • enterocytes: 46 nCPM
  • endometrial ciliated cells: 27 nCPM
  • other brain neurons: 18 nCPM
  • extravillous trophoblasts: 12 nCPM
  • ependymal cells: 12 nCPM
  • paneth cells: 12 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 24 nTPM
  • midbrain: 19 nTPM
  • pons: 14 nTPM
  • hypothalamus: 3.5 nTPM
  • thalamus: 2.1 nTPM
  • choroid plexus: 2 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC17A8.

Disease | AllUniProt

Conditions SLC17A8 is implicated in, by any mechanism.

  • Deafness, autosomal dominant, 25 (DFNA25) MIM:605583

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 362 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Autosomal dominant nonsyndromic hearing loss 25

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.61
gnomAD pLI
0
gnomAD missense Z
0.83
DepMap mean gene effect
0.04
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC17A8 as an antibody target. Whether an autoantibody or antibody against SLC17A8 could matter depends on whether native SLC17A8 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC17A8 is annotated at the cell surface, where native SLC17A8 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC17A8 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC17A8. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...